GlassScriptPhysician profile
Katie M Harjes
NPI 1922588268
$3,106.04
in general payments reported to CMS, 2019-2025
24 companies · $20.78 in 2025
The $20.78 reported for 2025 was less than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $773 · 2022: $473 · 2023: $1,165 · 2024: $674 · 2025: $20.78.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,860.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,859.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $493.54 | 2021-2024 | |
| Amgen INC. | $462.79 | 2021-2024 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $327.01 | 2021-2023 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $310.84 | 2021-2024 | Lifevest |
| Atricure, INC. | $255.95 | 2024 | |
| Abbott Laboratories | $176.29 | 2023-2024 | Gallant, Aveir |
| Boston Scientific Corporation | $170.31 | 2021-2024 | Lux-Dx Insertable Cardiac Monitor |
| Novo Nordisk INC | $160.38 | 2021-2023 | Ozempic |
| Zoll Respicardia, INC. | $147.06 | 2023-2025 | Remede System |
| Sanofi-Aventis U.S. LLC | $123.22 | 2023-2024 | |
| Kestra Medical Technology Services, INC. | $91.60 | 2023-2024 | Assure Wcd |
| Biosense Webster, INC. | $70.91 | 2023 | Carto 3 |
| Astrazeneca Pharmaceuticals LP | $37.78 | 2021 | |
| Esperion Therapeutics, INC. | $37.21 | 2021 | |
| Impulse Dynamics (USA) INC. | $34.00 | 2024 | Optimizer |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acacia Pharma INC | $27.89 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $26.99 | 2023 | Verquvo |
| Cvrx, INC. | $26.61 | 2023 | Barostim Neo System |
| Edwards Lifesciences Corporation | $25.59 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $24.92 | 2021-2023 | Camzyos |
| Janssen Pharmaceuticals, INC | $20.27 | 2023 | Xarelto |
| Altathera Pharmaceuticals LLC | $19.42 | 2023 | Sotalol Hydrochloride |
| Kiniksa Pharmaceuticals, LTD. | $18.84 | 2023 | Arcalyst |
| Amarin Pharma, INC. | $16.62 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katie Harjes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.